Literature DB >> 10372752

Cardiovascular and neurological toxicity of venlafaxine.

D Blythe1, L P Hackett.   

Abstract

1. We report a case of venlafaxine overdose and describe pharmacokinetic data on drug disposition. 2. Case report. Serial venlafaxine levels were measured and drug half-life calculated and compared to data at therapeutic concentrations. Metabolite concentrations were also measured and the potential for toxicity described with reference to individual variation in such metabolism 3. Venlafaxine can cause significant cardiac and neurotoxicity. Its potential for causing such toxicity may be dependent on whether an individual has the extensive metaboliser cytochrome CYP2D6 phenotype or the poor metaboliser phenotype

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10372752     DOI: 10.1191/096032799678840165

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  8 in total

Review 1.  Third-generation antidepressants: do they offer advantages over the SSRIs?

Authors:  J S Olver; G D Burrows; T R Norman
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 2.  Acute poisoning: understanding 90% of cases in a nutshell.

Authors:  S L Greene; P I Dargan; A L Jones
Journal:  Postgrad Med J       Date:  2005-04       Impact factor: 2.401

3.  Pharmacokinetic/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdose.

Authors:  Bruno Mégarbane; Vanessa Bloch; Nicolas Deye; Frédéric J Baud
Journal:  Intensive Care Med       Date:  2006-11-11       Impact factor: 17.440

4.  A fatal case of venlafaxine overdose.

Authors:  George M Bosse; Henry A Spiller; Aaron M Collins
Journal:  J Med Toxicol       Date:  2008-03

Review 5.  PharmGKB summary: venlafaxine pathway.

Authors:  Katrin Sangkuhl; Julia C Stingl; Miia Turpeinen; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-01       Impact factor: 2.089

Review 6.  Venlafaxine extended-release: a review of its use in the management of major depression.

Authors:  K Wellington; C M Perry
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 7.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 8.  'Atypical' antidepressants in overdose: clinical considerations with respect to safety.

Authors:  Nicholas A Buckley; Thomas A Faunce
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.